GSK
1 year ago ⋅ English ⋅ 6 min read
Newsroom
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients

For investors and media only- 48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response, transfusion independence and splenic response in th... Read More
GSK
1 year ago ⋅ English ⋅ 5 min read
Newsroom
PERLA phase II trial of Jemperli (dostarlimab) plus chemotherapy shows positive results in first-line metastatic non-squamous non-small cell lung cancer

For media and investors only- PERLA is the largest global head-to-head trial of PD-1 inhibitors in this patient population- Confirmed objective response rate was 46% in patients treated... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer

For media and investors only- Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival- RUBY is the only first... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis

For media and investors only- Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpointsGSK pl... Read More
GSK
1 year ago ⋅ English ⋅ 6 min read
Newsroom
New global survey reveals opportunities to address organ damage risk with people living with lupus earlier in the course of their disease

For media and investors only- Survey examined healthcare professional approaches to preventing organ damage – which impacts many people living with lupus within five years of diag... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf)... Read More